As of December 31, 2024, American Oncology Network, Inc. carries a market capitalization of 137.79M, placing it among publicly traded companies globally. Its enterprise value stands at 366.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 137.79M |
| Enterprise Value | 366.74M |
As of December 31, 2024, American Oncology Network, Inc. has 27.23M shares outstanding.
| Shares Outstanding | 27.23M |
These figures are as of December 31, 2024. The price-to-sales ratio is 0.04, and the price-to-book ratio stands at -2.98.
| PS Ratio | 0.04 |
| PB Ratio | -2.98 |
| P/TBV Ratio | -2.31 |
| P/FCF Ratio | -4.16 |
| P/OCF Ratio | -15.20 |
As of December 31, 2024, American Oncology Network, Inc. trades at an EV/EBITDA multiple of 188.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 366.74M versus a market cap of 137.79M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.21 |
| EV / EBITDA | 188.84 |
As of December 31, 2024, American Oncology Network, Inc. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 136.44, indicating elevated leverage, while an interest coverage ratio of 0.28 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.53 |
| Quick Ratio | 1.21 |
| Debt / Equity | 136.44 |
| Debt / EBITDA | 75.88 |
| Interest Coverage | 0.28 |
These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -0.94, reflecting losses generated across the asset base. The company generates approximately 1.08M in revenue per employee across its workforce of 1,622.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 31.19 indicates how many times American Oncology Network, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -0.94 |
| Revenue Per Employee | 1.08M |
| Employee Count | 1,622.25 |
| Inventory Turnover | 31.19 |
Over the twelve months ended December 31, 2024, American Oncology Network, Inc. recorded 2.50M in income tax expense. The company reported a pretax loss of -24.61M and -3.97M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 2.50M |
As of the close on November 16, 2026, American Oncology Network, Inc.'s stock has gained approximately 123.21% over the past 52 weeks. The 50-day moving average sits at 14.16, while the 200-day moving average is 11.50.
| 52-Week Price Change | 123.21% |
| 50-Day Moving Average | 14.16 |
| 200-Day Moving Average | 11.50 |
Over the twelve months ended December 31, 2024, American Oncology Network, Inc. generated 1.76B in revenue and converted that into -3.97M in net income, yielding earnings per share of -1.27. EBITDA reached 1.94M, while operating income came in at -16.09M.
| Revenue | 1.76B |
| Gross Profit | 117.85M |
| Operating Income | -16.09M |
| Pretax Income | -24.61M |
| Net Income | -3.97M |
| EBITDA | 1.94M |
| EBIT | -17.43M |
| Earnings Per Share (EPS) | -1.27 |
As of December 31, 2024, American Oncology Network, Inc. holds 72.64M in cash and equivalents against 147.37M in total debt, resulting in a net debt position of 28.02M. Total book value stands at -46.21M, with working capital of 114.63M providing operational flexibility.
| Cash & Cash Equivalents | 72.64M |
| Total Debt | 147.37M |
| Net Debt | 28.02M |
| Equity (Book Value) | -46.21M |
| Book Value Per Share | -1.70 |
| Working Capital | 114.63M |
American Oncology Network, Inc. produced -4.94M in operating cash flow over the twelve months ended December 31, 2024. After subtracting -20.95M in capital expenditures, free cash flow totaled -25.90M - equivalent to -1.74 per share.
| Operating Cash Flow | -4.94M |
| Capital Expenditures | -20.95M |
| Free Cash Flow | -25.90M |
| FCF Per Share | -1.74 |
Over the twelve months ended December 31, 2024, American Oncology Network, Inc. posted a gross margin of 6.70, reflecting its pricing power and cost economics. The operating margin of -0.91 and net profit margin of -0.23 provide insight into operational efficiency.
| Gross Margin | 6.70 |
| Operating Margin | -0.91 |
| Pretax Margin | -1.40 |
| Profit Margin | -0.23 |
| EBITDA Margin | 0.11 |
These figures cover the twelve months ended December 31, 2024. The dividend payout ratio of 10.00 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -24.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -30.24, meaning American Oncology Network, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Payout Ratio | 10.00 |
| Shareholder Yield | -30.24 |
| FCF Yield | -24.05 |
As of December 31, 2024, American Oncology Network, Inc. has an Altman Z-Score of 3.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.95 |